ArticleScientific reports2025
Circular RNA circNRIP1 promotes glioma progression by regulating the miR-106a-5p/GPR133 pathway.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Upregulated CircRNAs With Efficacy in PreclinicalCancer genomics & proteomicsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioma is one of the most common and aggressive types of brain tumors, characterized by generally low survival rates. Circular RNAs (circRNAs) have been identified as key players in the development of glioma. Our study aims to investigate the effect of circNRIP1 on glioma progression and elucidate the underlying mechanisms involved. The mRNA expression of circNRIP1, miR-106a-5p, and GPR133 was determined using qRT-PCR. The protein expression of N-cadherin, E-cadherin, fibronectin, vimentin, and GPR133 in glioma cells and tissues was measured through Western blotting and IHC assays. Cell counting kit-8 (CCK-8), wound healing, and transwell assays were used to determine cell proliferation, migration, and invasion, respectively. The dual-luciferase reporter assay was utilized to elucidate the targeting interaction between miR-106a-5p and both circNRIP1 and GPR133. Finally, xenograft models were established to investigate the effects of circNRIP1 in vivo. The expression of circNRIP1 was significantly elevated in glioma cell lines and tissues, and this higher expression correlated with a reduced overall survival rate. Downregulation of circNRIP1 had been shown to inhibit the invasion, migration, proliferation, and epithelial-mesenchymal transition (EMT) of glioma cells and attenuate tumor growth in vivo. circNRIP1 functions as a molecular sponge for miR-106a-5p, consequently elevating the expression of GPR133. Additionally, upregulation of GPR133 could counteract the inhibition of the malignant phenotype of glioma cells caused by circNRIP1 knockdown. circNRIP1 knockdown suppresses glioma progression by elevating miR-106a-5p levels and simultaneously reducing GPR133 expression. The identified circNRIP1/miR-106a-5p/GPR133 axis could potentially be a therapeutic target for glioma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.